<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>7377</number>
    <updateDate>2023-08-09T15:30:26Z</updateDate>
    <updateDateIncludingText>2023-08-09T15:30:26Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2022-04-04</introducedDate>
    <congress>117</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 168, Number 59 (Monday, April 4, 2022)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. CURTIS:H.R. 7377.Congress has the power to enact this legislation pursuantto the following:Congress has the power to enact this legislation pursuantto the following: Article 1, Section 8 of the United StatesConstitution.[Page H4153]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2022-04-05T18:07:17Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2022-04-04T16:02:35Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Modernizing Therapeutic Equivalence Rating Determination Act</title>
        <congress>117</congress>
        <number>1463</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-04-29</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2022-04-05</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-04-04</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-04-04</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-04-04</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>C001114</bioguideId>
        <fullName>Rep. Curtis, John R. [R-UT-3]</fullName>
        <firstName>John</firstName>
        <lastName>Curtis</lastName>
        <party>R</party>
        <state>UT</state>
        <middleName>R.</middleName>
        <district>3</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001119</bioguideId>
        <fullName>Rep. Craig, Angie [D-MN-2]</fullName>
        <firstName>Angie</firstName>
        <lastName>Craig</lastName>
        <party>D</party>
        <state>MN</state>
        <district>2</district>
        <sponsorshipDate>2022-04-04</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects/>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2022-04-04</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2023-08-09T15:27:43Z</updateDate>
        <text><![CDATA[ <p><strong>Modernizing Therapeutic Equivalence Rating Determination Act</strong></p> <p>This bill requires the Food and Drug Administration (FDA) to provide a therapeutic equivalence rating for certain new drug applications if the applicant requests such a rating. </p> <p>Upon request in the application, the FDA must provide such a rating for a new drug application that relies on information from studies not conducted by the applicant and that the applicant does not have a right to reference or use (commonly referred to as a 505(b)(2) application). The FDA must provide the rating no later than 30 days after the application's approval. </p> <p>(A drug is a therapeutic equivalent of another if they produce the same clinical effect and have the same safety profile. Typically, for certain generic drugs, the FDA rates the therapeutic equivalence of that generic drug to another drug, such as the brand name version. Currently, an applicant seeking approval of a drug through a 505(b)(2) application typically only receives an equivalence rating by requesting one from the FDA in a separate petition.) </p>]]></text>
      </summary>
    </summaries>
    <title>Modernizing Therapeutic Equivalence Rating Determination Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Modernizing Therapeutic Equivalence Rating Determination Act</title>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Modernizing Therapeutic Equivalence Rating Determination Act</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to modernize therapeutic equivalence rating determinations.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2022-04-04T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr7377ih/xml/BILLS-117hr7377ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2022-04-05</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
